Suggestions
Bruce Leuchter
Partner at PJT Partners
Bruce Leuchter, M.D. is currently the President & CEO of Neurvati Neurosciences, a company focused on developing technologies for neurological and psychiatric disorders.12 He is no longer a Partner at PJT Partners, as he previously held that position.2
Dr. Leuchter has a diverse background spanning clinical practice, academia, finance, and biotechnology:
-
Medical Career:
- Completed residency training in Neurology and Psychiatry at New York Presbyterian Hospital and Weill Cornell Medical College23
- Served as Director of Clinical Neuropsychiatry at Weill Cornell Medical College23
- Maintains a voluntary faculty appointment in the Department of Psychiatry at Weill Cornell3
-
Financial Industry Experience:
-
Current Roles:
-
Education:
Dr. Leuchter's expertise spans clinical neuropsychiatry, biotechnology equity research, healthcare investment banking, and drug development.3 He is known for his passion for knowledge and commitment to serving patients and families in need across various roles in academia, clinical medicine, financial services, and industry.2
Highlights
I’m thrilled to announce that today GRIN Therapeutics, a Neurvati Neurosciences company, issued a press release announcing that the first patient has been dosed in the Honeycomb Study, our Phase 1B clinical trial for radiprodil in GRIN2B gain-of-function patients. The need for treatments of GRIN-related disorders is extremely high and initiating this clinical study is a major milestone for our company as well as for the GRIN Community. We are grateful to the GRIN clinicians, researchers, advocates, and families for their roles in advancing this study! Read the full press release here: https://lnkd.in/ejh_Jvpp #raredisease #epilepsyawareness #drugdevelopment
